Erminia Massarelli is a Lung Cancer Treatments and Mutations physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 306 publications with 12,282 citations (h-index 45); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 23 Oct 2026
Erminia Massarelli, MD, is affiliated with City Of Hope National Medical Center. The public record shows 306 publications with 12,282 citations (h-index 45), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 26 companies, 1 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Lung Cancer Treatments and Mutations
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 26 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 27 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 111.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- CISH Inactivated TILs in the Treatment of NSCLC
Sponsor: Intima Bioscience, Inc.
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
Sponsor: City of Hope Medical Center
Industry payments
Updated 23 Oct 2026
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20254 payments
- Janssen Biotech, Inc.Program year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year20259 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.1%Kinase inhibitor39.1%Tagrisso100%Part D<11 patientsMetabolism & gastrointestinal
32.8%Serotonin-3 Receptor Antagonist32.8%Ondansetron Hcl100%Part D<11 patientsNervous system
28.1%Phenothiazine28.1%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System
Beckman Research Institute/city of Hope
FY2025$207,424P30CA033572 - Protocol Review and Monitoring System
Beckman Research Institute/city of Hope
FY2024$204,363P30CA033572 - Protocol Review and Monitoring System
Beckman Research Institute/city of Hope
FY2023$159,308P30CA033572
Congress activity
Updated 23 Oct 2026
60 congress contributions (2007–2026) across AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:
- Abstract 7942: TAE226 reprograms immune-cold head and neck tumors to immune-hot, augmenting immunotherapy efficacy
AACR Annual Meeting
AACR2026Co-author - Abstract 3231: Inhibition of focal adhesion kinase enhances antitumor response of immune checkpoint inhibitor therapy in laryngeal cancer
AACR Annual Meeting
AACR2025Co-author - Abstract 7574: Exploring the therapeutic potential of proteasome inhibitors in targeting SOX2-driven LUSC and SCLC
AACR Annual Meeting
AACR2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
Clinical Trial2026 - Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Journal of clinical oncology
Clinical Trial2025 - Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Journal of clinical oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle1,395 citations2022
- 02NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021Article945 citations2021
- 03Non–Small Cell Lung Cancer, Version 4.2024Article863 citations2024
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/erminia-massarelli-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
uttyler.edu/academics/colleges-schools/medicine/departments/internal-medicine/division-hematology-and-oncology/faculty-staff/erminia-massarelli.php
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uttyler.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Naples Faculty of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newswise.com ↗ - PhD in Molecular Oncology and Endocrinology
University of Naples Federico II
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uttyler.edu ↗ - MS in Biomedical Sciences
University of Texas Health Science Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uttyler.edu ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uttyler.edu ↗ - Member
American Association for Cancer Research (AACR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uttyler.edu ↗ - Member
International Association for the Study of Lung Cancer (IASLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uttyler.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newswise.com ↗
Secondary affiliations
appointments beyond the home institution- City of Hope Comprehensive Cancer Center
Duarte, California
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗ - UT Health East Texas HOPE Cancer Center
Division of Hematology and Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uttyler.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Swetha Thiruvengadam, MD
City Of Hope National Medical Center
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Stephen Gruber, MD
City Of Hope National Medical Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center